We recently published 7 Best ASX Stocks to Buy Right Now. Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks.
Mesoblast Limited (NASDAQ: MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure and other conditions. On November 25, Jefferies upgraded the company’s shares to Buy from Hold and increased the stock’s price target from AUD 3.00 to AUD 3.30. The financial firm cited Mesoblast Limited’s (NASDAQ: MESO) drug Ryoncil as a reason for its optimism. Jefferies explained that Ryoncil generated $30 million in gross revenue in Mesoblast Limited’s (NASDAQ: MESO) fiscal second quarter to meet Jefferies’ estimates. Jefferies also estimated that 14 patients completed treatment with the drug during the second quarter, and added that a total of 78 patients could complete treatment in 2026.
Mesoblast Limited (NASDAQ:MESO) has scored major gains with Ryoncil in 2026. For example, the company announced on October 3 that its drug had obtained a J-Code from Medicare and Medicaid Services. The classification was a significant victory for Mesoblast Limited (NASDAQ: MESO) as it allowed the drug to qualify for Medicare and Medicaid reimbursements and expanded its availability across the United States. Additionally, Ryoncil was the first drug of its type to receive this designation. The drug is designed for use in pediatric patients whose cells are attacked by donor cells after a stem cell transplant.
While we recognize MESO’s potential as an investment, our belief lies in the belief that certain AI stocks have more promise in terms of higher returns and have limited downside risk. If you’re looking for an extremely cheap AI stock that’s also a top beneficiary of Trump’s tariffs and relocation, check out our free report on the best AI stock in the short term.
READ NEXT: 30 stocks that should double in 3 years And 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published on Initiated Monkey.
